Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences

    CAMBRIDGE, Mass., June 9 /PRNewswire-FirstCall/ -- Vertex
Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will
webcast its presentations at three investor conferences:
    * Pacific Growth Equities Life Sciences Growth Conference on Tuesday, June
      13, 2006 at 10:30 a.m. PDT (1:30 p.m. EDT), presented by Ian Smith,
      Executive Vice President and Chief Financial Officer of Vertex

    * Goldman Sachs 27th Annual Global Healthcare Conference on Wednesday,
      June 14, 2006 at 3:00 p.m. PDT (6:00 p.m. EDT), presented by Joshua
      Boger, Ph.D., President and Chief Executive Officer of Vertex

    * Needham & Co. Fifth Annual Biotechnology and Medical Technology
      Conference on Thursday, June 15, 2006 at 8:30 a.m. EDT, presented by
      Lynne Brum, Vice President, Strategic Communications of Vertex
    Each presentation will be webcast live and may be accessed by visiting
the Vertex website at http://www.vrtx.com. A replay of the webcasts will
also be available on the Company's website for two weeks following the
presentations. To access the webcasts, go to Vertex's website and select
the desired presentation from the 'Events Calendar.' To ensure a timely
connection, it is recommended that users register at least 15 minutes prior
to the scheduled webcast.
    About Vertex
    Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. In collaboration
with GlaxoSmithKline, Vertex co-promotes the HIV protease inhibitor,
Lexiva.
    Lexiva is a registered trademark of the GlaxoSmithKline group of
companies.
    Vertex's press releases are available at http://www.vrtx.com.

    Vertex Contact:
    Lora Pike, Manager, Investor Relations, (617) 444-6755

SOURCE Vertex Pharmaceuticals Incorporated

http://www.vrtx.com/

http://www.prnewswire.com/comp/938395.html /
CONTACT:
Lora Pike, Manager of Investor Relations at
Vertex Pharmaceuticals Incorporated, +1-617-444-6755